Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance
- Autores
- Antonio, Marina; Maggio, Ruben Mariano
- Año de publicación
- 2018
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Mefenamic Acid (MFA) is a widely-used non-steroidal anti-inflammatory drug. MFA presents four possible crystal forms; Form I and Form II being the only two pure crystals that have been isolated and fully characterized. Both Form I and Form II were prepared following the literature and completely characterized by middle (MIR) and near (NIR) infrared spectroscopy, digital optical microscopy, differential scanning calorimetry, melting point and dissolution properties. In order to develop quantitative models to assess Form I in formulated products, two sets of samples, training (n = 10) and validation (n = 8) sets, were prepared by mixing both polymorphs and the matrix of excipient (simulating commercial tablets). The particle size of the samples was homogenized by sieving and samples were mechanically mixed. A batch of commercial tablets was gently disaggregated, sieved and mechanically mixed for further analysis. For each sample, full MIR and NIR spectra were acquired and used as input of partial least squares (PLS) algorithm separately. Method optimization and internal validation were performed by leave one out procedure. Full spectra and 5 PLS-factors were used for MIR; while, 5 PLS-factors and mean center spectra of full spectra were the optimal conditions for NIR. Accuracy and precision were assessed by evaluation of the actual vs. predicted curve of validation set; and by calculating validation set recoveries and deviations (104.3 ± 8.2% and 100.4 ± 1.0% for MIR and NIR respectively). Only NIR-PLS yielded acceptable results and low deviations during commercial samples evaluation (102.8 ± 0.1%). The same behavior was observed when spiked tablets were analyzed (103.5 ± 0.5%). Additionally, for the calibration set ten dissolution profiles (average of 6 curves each), were obtained under optimized test conditions (900 ml of buffer phosphate pH 9 with surfactant, apparatus II USP, 100 rpm, detection at 342 nm). A multiple linear regression (MLR) was carried out using dissolution profiles and Form I content. The developed MLR model could correlate dissolution profiles and polymorphic richness. This approach, coupled to previously developed NIR-PLS, may act as a valid tool to estimate dissolution profiles from solid forms.
Fil: Antonio, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Maggio, Ruben Mariano. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina - Materia
-
Polymorphism
Mefenamic Acid
MIR NIR
Chemometrics - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/87171
Ver los metadatos del registro completo
id |
CONICETDig_958b69378c447efad74869f2cb97b170 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/87171 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performanceAntonio, MarinaMaggio, Ruben MarianoPolymorphismMefenamic AcidMIR NIRChemometricshttps://purl.org/becyt/ford/1.4https://purl.org/becyt/ford/1Mefenamic Acid (MFA) is a widely-used non-steroidal anti-inflammatory drug. MFA presents four possible crystal forms; Form I and Form II being the only two pure crystals that have been isolated and fully characterized. Both Form I and Form II were prepared following the literature and completely characterized by middle (MIR) and near (NIR) infrared spectroscopy, digital optical microscopy, differential scanning calorimetry, melting point and dissolution properties. In order to develop quantitative models to assess Form I in formulated products, two sets of samples, training (n = 10) and validation (n = 8) sets, were prepared by mixing both polymorphs and the matrix of excipient (simulating commercial tablets). The particle size of the samples was homogenized by sieving and samples were mechanically mixed. A batch of commercial tablets was gently disaggregated, sieved and mechanically mixed for further analysis. For each sample, full MIR and NIR spectra were acquired and used as input of partial least squares (PLS) algorithm separately. Method optimization and internal validation were performed by leave one out procedure. Full spectra and 5 PLS-factors were used for MIR; while, 5 PLS-factors and mean center spectra of full spectra were the optimal conditions for NIR. Accuracy and precision were assessed by evaluation of the actual vs. predicted curve of validation set; and by calculating validation set recoveries and deviations (104.3 ± 8.2% and 100.4 ± 1.0% for MIR and NIR respectively). Only NIR-PLS yielded acceptable results and low deviations during commercial samples evaluation (102.8 ± 0.1%). The same behavior was observed when spiked tablets were analyzed (103.5 ± 0.5%). Additionally, for the calibration set ten dissolution profiles (average of 6 curves each), were obtained under optimized test conditions (900 ml of buffer phosphate pH 9 with surfactant, apparatus II USP, 100 rpm, detection at 342 nm). A multiple linear regression (MLR) was carried out using dissolution profiles and Form I content. The developed MLR model could correlate dissolution profiles and polymorphic richness. This approach, coupled to previously developed NIR-PLS, may act as a valid tool to estimate dissolution profiles from solid forms.Fil: Antonio, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Maggio, Ruben Mariano. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaElsevier Science2018-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/87171Antonio, Marina; Maggio, Ruben Mariano; Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance; Elsevier Science; Journal of Pharmaceutical and Biomedical Analysis; 149; 2-2018; 603-6110731-7085CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.jpba.2017.11.053info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0731708517320447info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:44:23Zoai:ri.conicet.gov.ar:11336/87171instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:44:23.848CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance |
title |
Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance |
spellingShingle |
Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance Antonio, Marina Polymorphism Mefenamic Acid MIR NIR Chemometrics |
title_short |
Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance |
title_full |
Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance |
title_fullStr |
Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance |
title_full_unstemmed |
Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance |
title_sort |
Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance |
dc.creator.none.fl_str_mv |
Antonio, Marina Maggio, Ruben Mariano |
author |
Antonio, Marina |
author_facet |
Antonio, Marina Maggio, Ruben Mariano |
author_role |
author |
author2 |
Maggio, Ruben Mariano |
author2_role |
author |
dc.subject.none.fl_str_mv |
Polymorphism Mefenamic Acid MIR NIR Chemometrics |
topic |
Polymorphism Mefenamic Acid MIR NIR Chemometrics |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.4 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Mefenamic Acid (MFA) is a widely-used non-steroidal anti-inflammatory drug. MFA presents four possible crystal forms; Form I and Form II being the only two pure crystals that have been isolated and fully characterized. Both Form I and Form II were prepared following the literature and completely characterized by middle (MIR) and near (NIR) infrared spectroscopy, digital optical microscopy, differential scanning calorimetry, melting point and dissolution properties. In order to develop quantitative models to assess Form I in formulated products, two sets of samples, training (n = 10) and validation (n = 8) sets, were prepared by mixing both polymorphs and the matrix of excipient (simulating commercial tablets). The particle size of the samples was homogenized by sieving and samples were mechanically mixed. A batch of commercial tablets was gently disaggregated, sieved and mechanically mixed for further analysis. For each sample, full MIR and NIR spectra were acquired and used as input of partial least squares (PLS) algorithm separately. Method optimization and internal validation were performed by leave one out procedure. Full spectra and 5 PLS-factors were used for MIR; while, 5 PLS-factors and mean center spectra of full spectra were the optimal conditions for NIR. Accuracy and precision were assessed by evaluation of the actual vs. predicted curve of validation set; and by calculating validation set recoveries and deviations (104.3 ± 8.2% and 100.4 ± 1.0% for MIR and NIR respectively). Only NIR-PLS yielded acceptable results and low deviations during commercial samples evaluation (102.8 ± 0.1%). The same behavior was observed when spiked tablets were analyzed (103.5 ± 0.5%). Additionally, for the calibration set ten dissolution profiles (average of 6 curves each), were obtained under optimized test conditions (900 ml of buffer phosphate pH 9 with surfactant, apparatus II USP, 100 rpm, detection at 342 nm). A multiple linear regression (MLR) was carried out using dissolution profiles and Form I content. The developed MLR model could correlate dissolution profiles and polymorphic richness. This approach, coupled to previously developed NIR-PLS, may act as a valid tool to estimate dissolution profiles from solid forms. Fil: Antonio, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina Fil: Maggio, Ruben Mariano. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina |
description |
Mefenamic Acid (MFA) is a widely-used non-steroidal anti-inflammatory drug. MFA presents four possible crystal forms; Form I and Form II being the only two pure crystals that have been isolated and fully characterized. Both Form I and Form II were prepared following the literature and completely characterized by middle (MIR) and near (NIR) infrared spectroscopy, digital optical microscopy, differential scanning calorimetry, melting point and dissolution properties. In order to develop quantitative models to assess Form I in formulated products, two sets of samples, training (n = 10) and validation (n = 8) sets, were prepared by mixing both polymorphs and the matrix of excipient (simulating commercial tablets). The particle size of the samples was homogenized by sieving and samples were mechanically mixed. A batch of commercial tablets was gently disaggregated, sieved and mechanically mixed for further analysis. For each sample, full MIR and NIR spectra were acquired and used as input of partial least squares (PLS) algorithm separately. Method optimization and internal validation were performed by leave one out procedure. Full spectra and 5 PLS-factors were used for MIR; while, 5 PLS-factors and mean center spectra of full spectra were the optimal conditions for NIR. Accuracy and precision were assessed by evaluation of the actual vs. predicted curve of validation set; and by calculating validation set recoveries and deviations (104.3 ± 8.2% and 100.4 ± 1.0% for MIR and NIR respectively). Only NIR-PLS yielded acceptable results and low deviations during commercial samples evaluation (102.8 ± 0.1%). The same behavior was observed when spiked tablets were analyzed (103.5 ± 0.5%). Additionally, for the calibration set ten dissolution profiles (average of 6 curves each), were obtained under optimized test conditions (900 ml of buffer phosphate pH 9 with surfactant, apparatus II USP, 100 rpm, detection at 342 nm). A multiple linear regression (MLR) was carried out using dissolution profiles and Form I content. The developed MLR model could correlate dissolution profiles and polymorphic richness. This approach, coupled to previously developed NIR-PLS, may act as a valid tool to estimate dissolution profiles from solid forms. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-02 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/87171 Antonio, Marina; Maggio, Ruben Mariano; Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance; Elsevier Science; Journal of Pharmaceutical and Biomedical Analysis; 149; 2-2018; 603-611 0731-7085 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/87171 |
identifier_str_mv |
Antonio, Marina; Maggio, Ruben Mariano; Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance; Elsevier Science; Journal of Pharmaceutical and Biomedical Analysis; 149; 2-2018; 603-611 0731-7085 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jpba.2017.11.053 info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0731708517320447 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier Science |
publisher.none.fl_str_mv |
Elsevier Science |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842268663291314176 |
score |
13.13397 |